1. Home
  2. CABA vs TREE Comparison

CABA vs TREE Comparison

Compare CABA & TREE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.25

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Logo LendingTree Inc.

TREE

LendingTree Inc.

HOLD

Current Price

$27.37

Market Cap

533.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CABA
TREE
Founded
2017
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
495.7M
533.1M
IPO Year
2019
2008

Fundamental Metrics

Financial Performance
Metric
CABA
TREE
Price
$3.25
$27.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
4
Target Price
$14.50
$71.25
AVG Volume (30 Days)
4.2M
503.8K
Earning Date
05-14-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
10.26
443.31
EPS
N/A
1.90
Revenue
N/A
$1,117,324,000.00
Revenue This Year
N/A
$19.03
Revenue Next Year
N/A
$7.07
P/E Ratio
N/A
$14.76
Revenue Growth
N/A
24.12
52 Week Low
$1.44
$27.51
52 Week High
$4.23
$77.35

Technical Indicators

Market Signals
Indicator
CABA
TREE
Relative Strength Index (RSI) 58.51 26.31
Support Level $3.12 N/A
Resistance Level $3.34 $39.74
Average True Range (ATR) 0.22 1.16
MACD 0.02 -0.05
Stochastic Oscillator 68.32 5.50

Price Performance

Historical Comparison
CABA
TREE

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

About TREE LendingTree Inc.

LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.

Share on Social Networks: